- Main
A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo
- Taha, Taha Y;
- Suryawanshi, Rahul K;
- Chen, Irene P;
- Correy, Galen J;
- McCavitt-Malvido, Maria;
- O’Leary, Patrick C;
- Jogalekar, Manasi P;
- Diolaiti, Morgan E;
- Kimmerly, Gabriella R;
- Tsou, Chia-Lin;
- Gascon, Ronnie;
- Montano, Mauricio;
- Martinez-Sobrido, Luis;
- Krogan, Nevan J;
- Ashworth, Alan;
- Fraser, James S;
- Ott, Melanie
- Editor(s): Yount, Jacob S
- et al.
Published Web Location
https://doi.org/10.1371/journal.ppat.1011614Abstract
Despite unprecedented efforts, our therapeutic arsenal against SARS-CoV-2 remains limited. The conserved macrodomain 1 (Mac1) in NSP3 is an enzyme exhibiting ADP-ribosylhydrolase activity and a possible drug target. To determine the role of Mac1 catalytic activity in viral replication, we generated recombinant viruses and replicons encoding a catalytically inactive NSP3 Mac1 domain by mutating a critical asparagine in the active site. While substitution to alanine (N40A) reduced catalytic activity by ~10-fold, mutations to aspartic acid (N40D) reduced activity by ~100-fold relative to wild-type. Importantly, the N40A mutation rendered Mac1 unstable in vitro and lowered expression levels in bacterial and mammalian cells. When incorporated into SARS-CoV-2 molecular clones, the N40D mutant only modestly affected viral fitness in immortalized cell lines, but reduced viral replication in human airway organoids by 10-fold. In mice, the N40D mutant replicated at >1000-fold lower levels compared to the wild-type virus while inducing a robust interferon response; all animals infected with the mutant virus survived infection. Our data validate the critical role of SARS-CoV-2 NSP3 Mac1 catalytic activity in viral replication and as a promising therapeutic target to develop antivirals.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-